Peritoneal mesothelioma is a rare cancer that develops in the lining of the abdomen, known as the peritoneum. It is far less common than pleural mesothelioma, which affects the lining of the lungs, but both are most frequently linked to previous asbestos exposure.
Because peritoneal mesothelioma is uncommon and can be difficult to recognise in its early stages, accurate diagnosis and specialist treatment planning are essential. For patients in London, private specialist care offers direct access to a consultant oncologist, dedicated time to discuss diagnosis and treatment options, and the opportunity to involve a multidisciplinary team experienced in this rare disease.
Dr Dionysis Papadatos-Pastos is a consultant medical oncologist specialising in thoracic and rare cancers, including peritoneal mesothelioma, and sees patients privately at several London clinics. He works closely with surgical oncologists, radiologists and palliative care teams to ensure that each patient receives a carefully coordinated treatment plan.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredUnderstanding Peritoneal Mesothelioma
Peritoneal mesothelioma develops in the peritoneum, the thin membrane that lines the abdominal cavity and surrounds many of the abdominal organs. Like pleural mesothelioma, it is associated with asbestos exposure, although the link is less well understood and the disease is significantly rarer.
Because symptoms often develop gradually and can resemble other abdominal conditions, peritoneal mesothelioma is sometimes diagnosed at a more advanced stage. Treatment aims may include controlling the disease, relieving symptoms, improving quality of life and, in selected patients, achieving long-term disease control. As with all rare cancers, treatment is always individualised and based on thorough specialist assessment.
Why Private Specialist Care Makes a Difference
For patients with peritoneal mesothelioma, access to specialist expertise is particularly important given how rare the condition is. Private specialist care in London offers several important advantages:
- Rapid access — appointments are typically available within days, not weeks
- Dedicated consultation time — longer appointments allow for a thorough discussion of diagnosis, staging and all treatment options
- Second opinions — many patients seek private review after an NHS diagnosis, particularly given the rarity of this condition
- Personalised MDT input — private patients benefit from specialist multidisciplinary discussion involving surgical oncology, radiology and pathology expertise specific to peritoneal disease
- Continuity of care — consistent access to the same consultant throughout treatment
- Coordination with NHS care — private specialist review can complement rather than replace existing NHS treatment
For many patients, a private consultation provides the clarity and reassurance that can be difficult to obtain for a condition this rare within a standard NHS pathway.
Why Specialist Assessment Is Important
Peritoneal mesothelioma requires careful evaluation by clinicians experienced in this specific disease. Important factors include the extent of disease within the abdomen, biopsy findings, overall health, prior treatment history and patient priorities. Because peritoneal mesothelioma is rare, specialist input — ideally from a centre with experience in this condition — helps ensure that treatment decisions are appropriate and well-coordinated.
When Private Specialist Review May Be Helpful
Patients often seek private specialist input when:
- they have recently received a diagnosis of peritoneal mesothelioma and want a thorough explanation
- treatment options appear complex or unclear
- they are considering surgery, chemotherapy or immunotherapy and want to understand eligibility and expectations
- they wish to obtain a second opinion before committing to a treatment plan
- symptom management, including abdominal swelling or discomfort, requires careful and ongoing planning
- they want dedicated time with a specialist to discuss their situation in full
Because peritoneal mesothelioma is rare, specialist review provides valuable clarity that can significantly reduce anxiety at a difficult time.
Surgery: Cytoreductive Surgery and HIPEC
In selected patients with peritoneal mesothelioma, surgery can play a more central role than it typically does in pleural disease. Cytoreductive surgery (CRS) aims to remove as much visible tumour as possible from the abdominal cavity.
In some cases, CRS is combined with hyperthermic intraperitoneal chemotherapy (HIPEC), in which heated chemotherapy is delivered directly into the abdominal cavity at the time of surgery. This approach is only suitable for carefully selected patients, depending on the extent of disease, overall fitness and specialist surgical assessment. A private consultation allows these criteria to be discussed in detail and without time pressure, including a realistic explanation of what the procedure involves and its potential risks and benefits.
Systemic Chemotherapy
For patients who are not candidates for cytoreductive surgery, or alongside surgery in some cases, systemic chemotherapy remains an important treatment option. As with pleural mesothelioma, combinations involving pemetrexed together with cisplatin or carboplatin are commonly used.
Treatment recommendations depend on overall fitness, kidney function and the extent of disease. In a private setting, chemotherapy planning is discussed in full at consultation, with time to address questions about side effects, scheduling and what to expect during treatment.
Immunotherapy for Peritoneal Mesothelioma
Immunotherapy is another systemic treatment option, used either alongside or instead of chemotherapy depending on individual circumstances. Rather than attacking cancer cells directly, immunotherapy helps the immune system recognise and respond to cancer.
For selected patients with peritoneal mesothelioma, immunotherapy combinations may represent an effective treatment option, particularly when surgery is not suitable or when disease has progressed despite chemotherapy. As with all systemic treatments, careful monitoring is required because immune-related side effects can affect different organs. Private specialist review allows patients to explore immunotherapy eligibility in detail, including discussion of likely benefits, potential side effects and monitoring requirements.
Managing Ascites and Abdominal Symptoms
A build-up of fluid in the abdomen, known as ascites, is common in peritoneal mesothelioma and may cause swelling, discomfort and breathlessness. Procedures to drain or manage recurrent fluid build-up can significantly improve comfort and quality of life, and are an important part of ongoing care alongside active cancer treatment.
Supportive Care
Supportive care is an essential part of treatment for peritoneal mesothelioma and may include pain management, nutritional advice, management of abdominal symptoms, fatigue management, psychological support and palliative care services where appropriate. In a private setting, supportive care is integrated into the overall treatment plan from the outset and coordinated alongside active cancer treatment.
The Role of the MDT
Peritoneal mesothelioma cases benefit from discussion by a specialist multidisciplinary team (MDT), which may include medical oncologists, surgical oncologists, radiologists, pathologists, specialist nurses and palliative care specialists. Because the disease is rare, MDT discussion involving clinicians familiar with peritoneal mesothelioma specifically is particularly valuable in ensuring that treatment decisions reflect collective, relevant expertise. Private patients benefit from this MDT input as part of their specialist care pathway.
Conclusion
Peritoneal mesothelioma treatment may involve cytoreductive surgery with or without HIPEC, systemic chemotherapy, immunotherapy, management of ascites and other abdominal symptoms, and supportive care. Because the disease is rare and can present diagnostic challenges, specialist assessment and multidisciplinary discussion are essential.
For patients who want rapid access, dedicated consultation time and a thorough discussion of all available options, private specialist care in London offers a clear pathway to expert management of this rare condition. Dr Papadatos-Pastos sees patients privately at several London clinics and works with each patient to develop a treatment plan tailored to their individual situation.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to Common Questions About Peritoneal Mesothelioma
Peritoneal mesothelioma is a rare cancer that develops in the peritoneum, the lining of the abdominal cavity. It is less common than pleural mesothelioma, which affects the lining of the lungs, and is also most often associated with previous asbestos exposure.
Treatment options may include cytoreductive surgery, sometimes combined with hyperthermic intraperitoneal chemotherapy (HIPEC), systemic chemotherapy, immunotherapy, management of ascites and other symptoms, and supportive care. The most appropriate approach depends on the extent of disease, overall health and individual priorities.
Yes. Private specialist care offers rapid access to a consultant oncologist, longer appointment times and the opportunity to discuss all treatment options in detail. Many patients choose private care to complement their existing NHS treatment or to obtain a second opinion, particularly given how rare this condition is.
Cytoreductive surgery aims to remove as much visible tumour as possible from the abdominal cavity. In selected patients, this is combined with HIPEC, where heated chemotherapy is delivered directly into the abdomen during surgery. This approach is only suitable for carefully selected patients following specialist assessment.
Immunotherapy is a systemic treatment option that may be used alongside or instead of chemotherapy, depending on individual circumstances. It works by helping the immune system recognise and respond to cancer cells. A private consultation allows eligibility, expected benefits and potential side effects to be discussed thoroughly.
No. Both are forms of mesothelioma and are typically linked to asbestos exposure, but they affect different parts of the body. Pleural mesothelioma affects the lining of the lungs, while peritoneal mesothelioma affects the lining of the abdomen. Symptoms, diagnosis and treatment approaches differ between the two.
Private appointments with a specialist are typically available within a few days. This can be particularly important for patients who have recently received a diagnosis of a rare condition and want prompt expert guidance.
Because peritoneal mesothelioma is rare, treatment decisions benefit from input from multiple specialists, including surgical oncology expertise specific to this disease. Private patients have access to MDT discussion as part of their care pathway.
